Kwality Pharmaceuticals
- Market cap
- ₹ 3,735 Cr.
- P/E
- 46.9x
- P/B
- 11.32x
- 52-week range
- 1,561 – 3,949
- ROE
- 23%
- ROCE
- 24%
- Dividend yield
- 0%
- Debt / equity
- 0.39
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Kwality Pharmaceuticals Limited is an India-based company, which engages in the manufacturing & trading in pharmaceuticals & allied products. It engages in the business of manufacturers, buyers and sellers of and dealers in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations. It also engages in research and development activities. It manufactures exports pharmaceutical formulations in liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments, external preparations, oral rehydration solutions (ORS), and others in various categories like beta lactam and non-beta lactam, hormones, cytotoxic (oncology) and effervescent. The Company has approximately 48 different sections available at their production centers. Its subsidiary is Kwality Pharmaceuticals Africa Limitada.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Kwality Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)46.9 against a typical 34.3: pricier than most peers (1st = cheapest).151st of 220
- Sales growth+45.9% against a typical +15.6% from a year earlier.33rd of 197
- Profit growth+116.7% against a typical +18.9% from a year earlier.27th of 160
- Share price, 3 months+41.8% against a typical −0.5%.16th of 200
- Size₹ 3,735.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).61st of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by ICRA- The company stopped sharing information with CRISIL.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]BBB+ | Stable | 7 May 2026 |
| CRISIL | Crisil B(Issuer Not Cooperating) | Stable | 25 Sep 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 7 May 2026 | ▲ Upgrade6 notches | [ICRA]B+ ISSUER NOT COOPERATING → [ICRA]BBB+ | — | ICRA | ₹ 200 Cr. | |
| 5 Dec 2025 | Rating action | [ICRA]B+ ISSUER NOT COOPERATING | — | ICRA | ₹ 65 Cr. | |
| 25 Sep 2025 | Reaffirmed | Crisil B(Issuer Not Cooperating) | — | CRISIL | ₹ 52 Cr. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70 | 78 | 92 | 80 | 90 | 84 | 116 | 111 | 111 | 123 | 157 | 162 |
| Expenses | 54 | 61 | 71 | 63 | 70 | 67 | 90 | 87 | 86 | 93 | 118 | 121 |
| Operating Profit | 15 | 17 | 21 | 17 | 20 | 18 | 26 | 24 | 25 | 30 | 39 | 41 |
| OPM % | 22% | 21% | 22% | 22% | 22% | 21% | 22% | 22% | 23% | 24% | 25% | 25% |
| Other Income | 0 | 1 | −7 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Interest | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 |
| Depreciation | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 | 18 | 22 | 32 | 34 |
| Tax % | 24% | 21% | 29% | 25% | 33% | 25% | 24% | 30% | 23% | 28% | 20% | 25% |
| Net Profit | 6 | 8 | 4 | 8 | 8 | 9 | 14 | 12 | 14 | 16 | 25 | 26 |
| EPS in Rs | 6.01 | 7.41 | 4.2 | 8.06 | 8.16 | 8.22 | 13.96 | 11.5 | 13.61 | 15.43 | 24.38 | 24.69 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 21%
- 5 Years
- 14%
- 3 Years
- 26%
- TTM
- 38%
- 10 Years
- 44%
- 5 Years
- 35%
- 3 Years
- 29%
- TTM
- 88%
- 10 Years
- 66%
- 5 Years
- 51%
- 3 Years
- 113%
- TTM
- —
- 10 Years
- 26%
- 5 Years
- 27%
- 3 Years
- 18%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Kwality Pharmaceuticals | ₹ 3,693.00 | ₹ 3,735 Cr. | 46.9x | 11.3x | 23% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Aditya Arora
- Chief Financial Officer, Executive Director
- Gurpreet Kaur
- Compliance Officer, Company Secretary
- Ramesh Kumar
- Managing Director, Whole Time Director
- Ajay Kumar Arora
- Whole Time Director
- Anju Arora
- Whole Time Director
- Geeta Arora
- Whole Time Director
- Shankar Dayal
- Chief Domestic Sales Officer
- Neeraj Lakhanpal
- Chief Export Sales Officer
Prices are delayed and for information only. Nothing on this page is investment advice.